The final, formatted version of the article will be published soon.
REVIEW article
Front. Neurol.
Sec. Movement Disorders
Volume 15 - 2024 |
doi: 10.3389/fneur.2024.1462240
Neuroprotective effects of GLP-1 class drugs in Parkinson's disease
Provisionally accepted
LV Dongliang
1
Feng Peng
1
Li Dongfang
1*
Liu Zhaona
1*
Xue Cunshui
1*
Bai Bo
1*
Christian Hölscher
2- 1 Department of Neurology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
- 2 Academy of Chinese Medical Science, Henan University of Traditional Chinese Medicine, Zhengzhou, China
Parkinson's disease (PD) is a chronic, progressive neurological disorder primarily affecting motor control, clinically characterized by resting tremor, bradykinesia, rigidity, and other symptoms that significantly diminish the quality of life. Currently, available treatments only alleviate symptoms without halting or delaying disease progression. There is a significant association between PD and type 2 diabetes mellitus (T2DM), possibly due to shared pathological mechanisms such as insulin resistance, chronic inflammation, and mitochondrial dysfunction. PD is caused by a deficiency of dopamine, a neurotransmitter in the brain that plays a critical role in the control of movement. Glucose metabolism and energy metabolism disorders also play an important role in the pathogenesis of PD.This review investigates the neuroprotective mechanisms of glucagon-like peptide-1 (GLP-1) and its receptor agonists, offering novel insights into potential therapeutic strategies for PD. GLP-1 class drugs, primarily used in diabetes management, show promise in addressing PD's underlying pathophysiological mechanisms, including energy metabolism and neuroprotection. These drugs can cross the blood-brain barrier, improve insulin resistance, stabilize mitochondrial function, and enhance neuronal survival and function. Additionally, they exhibit significant anti-inflammatory and antioxidative stress effects, which are crucial in neurodegenerative diseases like PD. Research indicates that GLP-1 receptor agonists could improve both motor and cognitive symptoms in PD patients, marking a potential breakthrough in PD treatment and prevention. Further exploration of GLP-1's molecular mechanisms in PD could provide new preventive and therapeutic approaches, especially for PD patients with concurrent T2DM. By targeting both metabolic and neurodegenerative pathways, GLP-1 receptor agonists represent a multifaceted approach to PD treatment, offering hope for better disease management and improved patient outcomes.
Keywords: Parkinson's disease, diabetes, Glucagon-Like Peptide 1, Insulin, Energy Metabolism, Neuroprotection
Received: 09 Jul 2024; Accepted: 14 Nov 2024.
Copyright: © 2024 Dongliang, Peng, Dongfang, Zhaona, Cunshui, Bo and Hölscher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Li Dongfang, Department of Neurology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Liu Zhaona, Department of Neurology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Xue Cunshui, Department of Neurology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Bai Bo, Department of Neurology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.